Positive News SentimentPositive NewsNASDAQ:TELO Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis $1.02 +0.02 (+2.15%) Closing price 04:00 PM EasternExtended Trading$1.00 -0.02 (-1.96%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Telomir Pharmaceuticals Stock (NASDAQ:TELO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TELO alerts:Sign Up Key Stats Today's Range$1.01▼$1.0750-Day Range$0.98▼$1.2552-Week Range$0.89▼$1.58Volume54,829 shsAverage Volume117,954 shsMarket Capitalization$70.16 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingHold Company Overview Telomir Pharmaceuticals, Inc. is a development-stage biotechnology company focused on therapies intended to address age-related diseases and conditions. The company’s research is centered on telomere biology, a field involving the protective DNA sequences at the ends of chromosomes that are associated with cellular aging. Telomir’s lead investigational product is TELOMIR-1, an orally administered small-molecule compound being developed to promote telomere lengthening and support cellular health. The company is evaluating potential applications in human medicine and veterinary medicine, although TELOMIR-1 remains investigational and has not been established as a safe or effective treatment for any disease. Telomir Pharmaceuticals is headquartered in Jacksonville, Florida, and its shares trade on the Nasdaq Capital Market under the symbol TELO. As a biotechnology company in the research and development stage, it does not currently have an approved commercial product.AI Generated. May Contain Errors. Read More Telomir Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreTELO MarketRank™: 2.87622612287 of 5 starsTelomir Pharmaceuticals scored higher than 58% of companies evaluated by MarketBeat, and ranked 443rd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingTelomir Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTelomir Pharmaceuticals has a consensus price target of $4.00, representing about 288.7% upside from its current price of $1.03.Amount of Analyst CoverageTelomir Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Telomir Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Telomir Pharmaceuticals is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Telomir Pharmaceuticals is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTelomir Pharmaceuticals has a P/B Ratio of 6.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Telomir Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.34% of the float of Telomir Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTelomir Pharmaceuticals has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Telomir Pharmaceuticals has recently decreased by 6.74%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTelomir Pharmaceuticals does not currently pay a dividend.Dividend GrowthTelomir Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentTelomir Pharmaceuticals has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Telomir Pharmaceuticals this week, compared to 1 article on an average week.Search Interest1 people have searched for TELO on MarketBeat in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Telomir Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders16.36% of the stock of Telomir Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsTelomir Pharmaceuticals has minimal institutional ownership at this time.Read more about Telomir Pharmaceuticals' insider trading history. Receive TELO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telomir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TELO Stock News HeadlinesTelomir Pharmaceuticals, Inc. announced that it has received $5.618228 million in fundingOctober 6, 2026 | marketscreener.comMTelomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the CompanyOctober 6, 2026 | globenewswire.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.October 27 at 1:00 AM | Crypto 101 Media (Ad)Research shows Telomir-Zn might slow bone cancer in dogsSeptember 24, 2026 | msn.comMaxim Initiates Telomir Pharmaceuticals at Buy With $4 Price TargetSeptember 18, 2026 | marketscreener.comMTelomir Publishes Data Validating Telomir-Zn For AMD Alongside Cancer Indications; Stock UpSeptember 17, 2026 | rttnews.comTelomir-Zn Preclinical Data Highlight Retinal Regeneration PotentialSeptember 17, 2026 | tipranks.comTelomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)September 17, 2026 | globenewswire.comSee More Headlines TELO Stock Analysis - Frequently Asked Questions How have TELO shares performed this year? Telomir Pharmaceuticals' stock was trading at $1.33 at the beginning of 2026. Since then, TELO stock has decreased by 22.6% and is now trading at $1.0290. How were Telomir Pharmaceuticals' earnings last quarter? Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) released its quarterly earnings results on Thursday, August, 13th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by $0.72. When did Telomir Pharmaceuticals IPO? Telomir Pharmaceuticals (TELO) raised $7 million in an initial public offering on Friday, February 9th 2024. The company issued 1,000,000 shares at $7.00 per share. Kingswood Investments acted as the underwriter for the IPO. How do I buy shares of Telomir Pharmaceuticals? Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today10/27/2026Next Earnings (Estimated)12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 4 weeks, TELO's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TELO Previous SymbolNASDAQ:TELO CIK1971532 Webtelomirpharma.com Phone(786) 396-6723FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for Telomir Pharmaceuticals$4.00 High Price Target$4.00 Low Price Target$4.00 Potential Upside/Downside+292.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-102.70% Return on Assets-90.75% Debt Debt-to-Equity RatioN/A Current Ratio16.16 Quick Ratio16.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book6.00Miscellaneous Outstanding Shares68,780,000Free Float57,523,000Market Cap$70.16 million OptionableN/A Beta-0.31 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:TELO) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
